实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (3): 366-369.doi: 10.3969/j.issn.1672-5069.2024.03.012

• 自身免疫性肝病 • 上一篇    下一篇

急性表现与非急性表现的自身免疫性肝炎患者临床和肝组织病理学特征分析*

金伯旬, 张丽, 娜仁图雅, 齐丽艳, 边新渠, 刘海霞, 王鑫, 栗光明   

  1. 100069 北京市 首都医科大学附属北京佑安医院重症医学科(金伯旬,边新渠,刘海霞,王鑫,栗光明);内蒙古自治区呼和浩特市第二医院肝病重症科(张丽,娜仁图雅,齐丽艳)
  • 收稿日期:2023-05-05 出版日期:2024-05-10 发布日期:2024-06-11
  • 通讯作者: 栗光明,E-mail:peptuma@126.com
  • 作者简介:金伯旬,男,40岁,医学博士,主治医师。研究方向:重症肝病治疗。E-mail:peptuma@163.com
  • 基金资助:
    * 北京市丰台区卫生计生委员会科研项目(编号:2018-67)

Clinical and liver histopathological features in patients with acute and non-acute presentation of autoimmune hepatitis

Jin Boxun, Zhang Li, Na Ren Tuya, et al   

  1. Department of Critical Care Medicine, You 'an Hospital, Capital Medical University, Beijing 100069, China
  • Received:2023-05-05 Online:2024-05-10 Published:2024-06-11

摘要: 目的 探讨急性表现的自身免疫性肝炎(AP-AIH)与非急性表现的自身免疫性肝炎(NAP-AIH)患者临床和肝组织病理学特征的差异,为准确诊断和治疗提供依据。方法 2017年10月~2022年10月我院诊治AP-AIH患者30例和NAP-AIH患者22例,常规行肝穿刺,通过医院标准化的电子病历系统搜集患者的病历资料。结果 两组年龄(54.0±14.5岁对53.4±15.0岁)和性别(男性23.3%对22.7%)比较,差异无统计学意义(P>0.05); AP-AIH组血清ALT、AST、TBIL、ALP、GGT和IgG水平分别为714.4(153,2061)U/L、590.5(147,2168)U/L、81.6(43.3,106.2)μmol/L、146.2(70.7,164)U/L、81.4(38.5,150.3)U/L和220.0(128.0,245.1)mg/L,均显著大于NAP-AIH组【分别为116.5(85,172)U/L、105.8(78,176)U/L、23.4(17.4,30.8)μmol/L、113.2(66.7,176.4)U/L、83.6(41.6,153.8)U/L和142.5(90.6,243.7)mg/L,P<0.05】;两组均接受标准的免疫抑制治疗,AP-AIH组应答率为80.0%,显著高于NAP-AIH组的54.5%(P<0.05);AP-AIH组肝组织肝细胞坏死、中重度肝细胞卵石样外观、卵石样外观区玫瑰花样结构、肝实质内浆细胞浸润和中重度界面性肝炎发生率分别为76.7%、50.0%、20.0%、33.3%和56.7%,均显著高于NAP-AIH组(分别为40.9%、22.7%、0.0%、13.6%和18.2%,P<0.05)。 结论 顾名思义,AP-AIH患者更多显示急性肝损伤的临床和组织病理学表现,对治疗应答率较高。

关键词: 自身免疫性肝炎, 急性表现, 组织病理学, 应答

Abstract: Objective This study was conducted to investigate the clinical and liver histopathological features in patients with acute (AP-AIH) and non-acute presentation of autoimmune hepatitis (NAP-AIH). Methods 30 patients with AP-AIH and 22 patients with NAP-AIH were encountered in our hospital between October 2017 and October 2022, and all patients underwent routinely liver biopsies. The clinical materials were retrieved from standardized electronic medical record data bank in our hospital. Results There were no significant differences as respect to the ages (54.0±14.5 yr vs. 53.4±15.0 yr) and the gender (male for 23.3% vs. 22.7%) between the two groups (P>0.05); serum ALT, AST, bilirubin, ALP, GGT and IgG levels in patients with AP-AIH were 714.4(153.0, 2061.0)U/L, 590.5(147.0,2168.0)U/L, 81.6(43.3, 106.2)μmol/L,146.2(70.7,164.0)U/L, 81.4(38.5, 150.3) U/L and 220.0(128.0, 245.1)mg/L, all significantly higher than [116.5(85.0,172.0)U/L,105.8(78.0, 176.0)U/L,23.4(17.4, 30.8)μmol/L, 113.2(66.7, 176.4)U/L, 83.6(41.6, 153.8) U/L and 142.5(90.6, 243.7)mg/L, respectively, P<0.05] in those with NAP-AIH; the response rate to standardized immunosuppression therapy in patients with AP-AIH was 80.0%, much higher than 54.5%(P<0.05)in those with NAP-AIH; the liver histological examination showed that the incidences of hepatocellular necrosis, moderate to severe cobblestone appearance of hepatocytes, hepatic rosette formation in cobblestone appearance areas, prominent plasma cell invasion in the liver parenchyma and moderate to severe interface hepatitis in patients with AP-AIH 76.7%, 50.0%, 20.0%, 33.3% and 56.7%, all significantly higher than 40.9%, 22.7%, 0.0%, 13.6% and 18.2% (P<0.05) in those with NAP-AIH. Conclusion The clinical and histological features in patients with AP-AIH are consistent with acute liver injuries, and respond to immunosuppression therapy relatively satisfactory.

Key words: Autoimmune hepatitis, Acute presentation, Histopathology, Response